Managers / Q1 2022 · view latest →
venBio Partners LLC
CIK 0001776382 · 1700 OWENS STREET, SUITE 595, SAN FRANCISCO, CA, 94158 · 415-522-0100
Summary
Venbio Partners LLC reported $451M in U.S.-listed holdings across 10 positions for Q1 2022.
The portfolio is heavily concentrated: ALXO alone accounts for 36.3% of reported value.
Compared with Q4 2021, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 78.8% · $355M
- Other · 21.0% · $95M
- ADR · 0.2% · $808,000
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CINCOR PHARMA INC | NEW | +1.98M | 1.98M | +$35M | $35M |
| HRMYHARMONY BIOSCIENCES HLDGS IN | TRIMMED | −1.20M | 1.54M | −$42M | $75M |
| ALXOALX ONCOLOGY HLDGS INC | HELD | +0 | 9.70M | −$45M | $164M |
| VENTYX BIOSCIENCES INC | HELD | +0 | 5.01M | −$32M | $68M |
| AKROAKERO THERAPEUTICS INC | HELD | +0 | 2.17M | −$15M | $31M |
| ELEVATION ONCOLOGY INC | HELD | +0 | 2.61M | −$9M | $7M |
| PHARVARIS N V | HELD | +0 | 2.30M | +$9M | $42M |
| IMPEL NEUROPHARMA INC | HELD | +0 | 2.76M | −$6M | $18M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ALXOALX ONCOLOGY HLDGS INChistory → | COM | 36.34% | $164M | 9.70M |
| 2 | HRMYHARMONY BIOSCIENCES HLDGS INhistory → | COM | 16.66% | $75M | 1.54M |
| 3 | VENTYX BIOSCIENCES INC | COM | 15.08% | $68M | 5.01M |
| 4 | PHARVARIS N V | COM | 9.26% | $42M | 2.30M |
| 5 | CINCOR PHARMA INC | COM | 7.70% | $35M | 1.98M |
| 6 | AKROAKERO THERAPEUTICS INChistory → | COM | 6.83% | $31M | 2.17M |
| 7 | IMPEL NEUROPHARMA INC | COM | 3.90% | $18M | 2.76M |
| 8 | CHECKMATE PHARMACEUTICALS IN | COM | 2.60% | $12M | 3.67M |
| 9 | ELEVATION ONCOLOGY INC | COM | 1.46% | $7M | 2.61M |
| 10 | VRNAVERONA PHARMA PLC | SPONSORED ADS | 0.18% | $808,000 | 161.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $281M | 6 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $216M | 6 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $176M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $115M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $124M | 7 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $171M | 7 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $194M | 6 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $232M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $282M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $667M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $353M | 8 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $276M | 7 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $323M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $432M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $351M | 9 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $451M | 10 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $555M | 9 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.0B | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $847M | 10 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.1B | 8 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.1B | 7 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $658M | 8 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $120M | 4 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $38M | 3 | May 26, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $233M | 6 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2019 | $211M | 6 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2019 | $225M | 6 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2019 | $123M | 4 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.